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Introduction
CAPS is a rare monogenic autoinflammatory syndrome
consisting of a spectrum of three conditions: Familial
cold autoinflammatory syndrome (FCAS), Muckle-
Wells syndrome (MWS), and the most severe form,
NOMID/CINCA. Progressive hearing loss is a charac-
teristic of severe CAPS [1]. Previous analyses showed
that long-term anakinra treatment stabilized the
progression of hearing loss [2,3]. CAPS patients with
different NLRP3 mutations have distinctly different tra-
jectories of hearing loss, suggesting a mutation-specific
risk that should be considered when making treatment
decisions [4].
Objectives
To characterize the correlation between different NLRP3
mutations and hearing loss in severe CAPS patients and to
evaluate whether long-term anakinra treatment stabilizes
the progression of hearing loss.
Methods
A prospective open-label study with long-term extension
including 43 patients with severe CAPS was conducted at
the National Institutes of Health [1,2]. The patients were
treated with anakinra for up to 5 years. The patients who
presented with NLRP3 mutations at baseline were further
classified based on the gene location (D303N versus other
locations). Hearing was monitored with audiogram which
was evaluated with four frequency (0.5/1/2/4 kHz) pure
tone average (4F-PTA), based on both air and bone
conduction in the ear with best and worst hearing. The
longitudinal changes in 4F-PTA were estimated with a
mixed model for repeated measures (MMRM).
Results
Altogether 22 patients provided pre and post treatment
audiogram data. NLRP3 mutation was identified in
18 (82%) patients, 7 (32%) presented with D303N and
11 (50%) with other locations (2 x T348M, G569R,
L264F, A374N, F443L, G326E, L632F, Q600P, V262A,
V351L). In a multivariate analysis, the baseline 4F-PTA
(ear with best hearing, air conduction) correlated with
both age (p=0.032) and location of NLRP3 mutation
(p=0.049) so that older patients and patients with muta-
tions outside of D303N presented with more hearing
loss. Following the initiation of the anakinra treatment,
no significant changes were seen in mean 4F-PTA at
any time point up to 5 years in either patients with
D303N or patients with other NLRP3 mutations in the
MMRM analysis adjusting for age; thus, hearing
remained stable. Comparable findings were seen in the
worst ear based on air conduction and for best/worst
ear based on bone conduction assessments.
Conclusion
Mutation-specific risk for hearing loss which is indepen-
dent of age was seen based on the baseline audiogram
data. Anakinra treatment for up to 5 years stabilized the
progression of hearing loss regardless of the mutation.
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